The Cancer Letter

Inside information on cancer research and drug development

NCI Trials

NCI Trials for June 2021

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The National Cancer Institute approved the following clinical research studies last month.  

For further information, contact the principal investigator listed.

Phase I – 10347

A Phase I Study with an Expansion Cohort of Duvelisib and Nivolumab in Mycosis Fungoides (MF) and SÈzary Syndrome (SS)

Yale University Cancer Center LAO

Mehta-Shah, Neha

(314) 747-7402

Phase I – 10450

A Phase 1b Trial of M3814 (Peposertib) in Combination with Lutetium 177 Dotatate for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Ohio State University Comprehensive Cancer Center LAO

Chauhan, Aman

(504) 278-0134

Phase II – A051902

A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas

Alliance for Clinical Trials in Oncology

Mehta-Shah, Neha

(314) 747-7955

Phase III – ANHL1931

A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination with Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

Children’s Oncology Group

Roth, Lisa Giulino

(212) 746-3400

Phase III – EAA171

Optimizing Prolonged Treatment In Myeloma Using MRD Assessment (OPTIMUM)

ECOG-ACRIN Cancer Research Group

Kumar, Shaji K.

(507) 284-5096

Phase Other – AMC-113

Observational Cohort Study of People Living with HIV Treated with CD19-Directed CAR T Cell Therapy for B-Cell Lymphoid Malignancies

AIDS Malignancy Consortium

Barta, Stefan Klaus

(215) 615-6506

Table of Contents

YOU MAY BE INTERESTED IN

White House

Tracking Trump’s early impact on cancer policy
Research and care disrupted, NCI programs face unpredictable future

The Trump administration did exactly what it said it would do to disorient anyone involved in making policy or touched by it. The president and his crew have “flooded the zone”—the term and the image are theirs, as is the strategy of dropping a flurry of executive orders and memoranda that shake the foundations of the American system of government, raising questions of legality and constitutionality, and, above all, making it a challenge for anyone to see the entire picture and think strategically.
By Paul Goldberg
Capitol Hill

With a spotlight on vaccines, abortion, Medicaid and Medicare, RFK Jr. goes before the Senate
The MAHA nominee trumpets radical transparency, but offers little clarity on his new agenda

In two raucous back-to-back hearings on Jan. 29 and Jan. 30, anti-vaccine crusader Robert F. Kennedy Jr. was grilled by members of the United States Senate Finance Committee and the Health, Education, Labor, and Pensions Committee as the Trump administration seeks his confirmation as secretary of the Department of Health and Human Services. 
By Claire Marie Porter
Guest Editorial

Cancer research fuels life-saving work

Over the past century, groundbreaking cancer research in the U.S. has led to life-saving medical advances that benefit patients worldwide. Scientists often devote their lives to making discoveries, putting their scientific endeavors ahead of status, income, or lifestyle. Investigators work tirelessly, often seven days a week, to solve complex medical problems. These efforts often lead to game-changing outcomes that help us understand difficult medical challenges, advance technologies and develop new therapies. 
By Ze’ev Ronai
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account